---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027344"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:39:08.769927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow Q2: record revenue $33.5M (+44% YoY), adj. EBITDA $11.0M (+144%); $69M equity offer, product acquisitions

## Summary
- Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.
- Record adjusted EBITDA of $11.0M, up 144% YoY; core gross margin improved to 78% from 73%.
- Completed $69M common stock offering and expanded Oaktree loan from $100M to $112.5M.
- Acquired North American rights to VEVYE (dry eye drug) and Santen portfolio including FLAREX, NATACYN, TOBRADEX ST.
- Reaffirmed 2023 guidance: net revenue $135-143M, adjusted EBITDA $44-50M.

## SEC filing metadata
- accession: 0001493152-23-027344
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/0001493152-23-027344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027344
- JSON: https://secwatch.observer/filing/0001493152-23-027344.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027344.txt

## Key facts
- Earnings Releases
  HARROW, INC. reported financial results for the second quarter and six months ended June 30, 2023.
  - Period: the second quarter and six months ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial results for the period ended June 30, 2023 and an update on recent corporate events.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315223027344/0001493152-23-027344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.